A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Vaccine

Volumn 26, Issue 17, 2008, Pages 2092-2099

  Tsuji, Takao ^a   Shimizu, Takeshi ^b   Sasaki, Keiko ^a   Tsukamoto, Kentaro ^a   Arimitsu, Hideyuki ^a   Ochi, Sadayuki ^a   Shimizu, Toshiyasu ^a   Taniguchi, Koki ^a   Noda, Masatoshi ^b   Neri, Paola ^c   Mori, Hiroshi ^c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Enterohemorrhagic Escherichia coli; Heat labile enterotoxin; Mucosal adjuvant; Nasal vaccine; Stx2B

Indexed keywords

BACTERIUM ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2; VEROTOXIN B ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FEMALE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TOXEMIA;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; LUNG; MICE; SHIGA TOXIN 1; SHIGA TOXIN 2; VACCINES, SUBUNIT;

EID: 41549158210     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.034     Document Type: Article

References (37)

1. Karmali M.A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 2 (1989) 15-38
2. Karmali M.A., Petric M., Louie S., and Cheung R. Antigenic heterogeneity of Escherichia coli verotoxins. Lancet 1 (1986) 164-165
3. Gianviti A., Rosmini F., Caprioli A., Corona R., Matteucci M.C., Principato F., et al., Italian HUS Study Group. Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in Italy. Pediatr Nephrol 8 (1994) 705-709
4. Griffin P.M., and Tauxe R.V. The epidemiology of infections caused by Escherichia coli O157: H7, other enterohemorrhagic. Epidemiol Rev 13 (1991) 60-98
5. Wen S.X., Teel L.D., Judge N.A., and O'Brien A.D. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24 (2006) 81142-81148
6. Jackson M.P., Newland J.W., Holmes R.K., and O'Brien A.D. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog 2 (1987) 147-153
7. Donohue-Rolfe A., Jacewicz M., and Keusch G.T. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol Microbiol 3 (1989) 1231-1236
8. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., and Keusch G.T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163 (1986) 1391-1404
9. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., and Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins. Eur J Biochem 171 (1988) 45-50
10. Obrig T.G., Moran T.P., and Brown J.E. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244 (1987) 287-294
11. Reisbig R., Olsnes S., and Eiklid K. The cytotoxic activity of Shigella toxin: evidence for catalytic inactivation of the 60S ribosomal subunit. J Biol Chem 256 (1981) 8739-8744
12. Mulvey G., Vanmaele R., Mrazek M., Cahill M., and Armstrong G.D. Affinity purification of Shiga-toxin I and Shiga-like toxin II. J Microbiol Methods 32 (1998) 247-252
13. Scotland S.M., Smith H.R., and Rowe B. Two distinct toxins active on Vero cells from Escherichia coli O157 [letter]. Lancet 2 (1985) 885-886
14. Takeda T., Yoshino K., Uchida H., Matsuda E., and Yamagata M. Epidemiological study of hemolytic uremic syndrome associated with enterohemorrhagic Escherichia coli in Japan. Nippon Rinsho 55 (1997) 693-699
15. Caprioli A., Luzzi I., Rosmini F., Resti C., Edefonti A., Perfumo F., et al. Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. J Infect Dis 169 (1994) 208-211
16. Strockbine N.A., Marques L.R., Newland J.W., Smith H.W., Holmes R.K., and O'Brien A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 53 (1986) 135-140
17. Bielaszewska M., Karmali M.A., and Petric M. Localization of verocytotoxin (VT) 2 and antigenic cross-reactivity of VT1 and VT2 in the rabbit model. In: Karmali M., and Goglio A. (Eds). Recent advances in verocytotoxin-producing Escherichia coli infection (1994), Elsevier Science, Amsterdam 249-252
18. Bielaszewska M., Clarke I., Karmali M.A., and Petric M. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun 65 (1997) 2509-2516
19. Downes F.P., Barrett T.J., Green J.H., Aloisio C.H., Spika J.S., Strockbine N.A., et al. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun 56 (1988) 1926-1933
20. Wadolkowski E.A., Burris J.A., and O'Brien A.D. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 58 (1990) 2438-2445
21. Wadolkowski E.A., Sung L.M., Burris J.A., Samuel J.E., and O'Brien A.D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 58 (1990) 3959-3965
22. Kleanthous H., Smith H.R., Scotland S.M., Gross R.J., Rowe B., Taylor C.M., et al. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. II. Microbiological aspects. Arch Dis Child 65 (1990) 722-727
23. Head S.C., Petric M., Richardson S., Roscoe M., and Karmali M.A. Purification and characterization of verocytotoxin 2. FEMS Microbiol Lett 51 (1988) 211-216
24. Marcato P., Mulvey G., Read R.J., Helm K.V., Nation P.N., and Glen D. Armstrong Immunoprophylactic Potential of Cloned Shiga Toxin 2 B Subunit. J Infect Dis 183 (2001) 435-443
25. Wen S.X., Teel L.D., Judge N.A., and O'Brien A.D. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci 103 (2006) 7082-7087
26. Sheoran A.S., Chapman-Bonofiglio S., Harvey B.R., Mukherjee J., Georgiou G., Donohue-Rolfe A., et al. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun 73 (2005) 4607-4613
27. Donohue-Rolfe A., Acheson D.W., Kane A.V., and Keusch G.T. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun 57 (1989) 3888-3893
28. Shimizu T., Kawakami S., Sato T., Sasaki T., Higashide M., Hamabata T., et al. The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli. Infect Immun 75 (2007) 2189-2200
29. Shimizu T., Sasaki K., Kato M., Arimitsu H., Ochi S., Yano T., et al. A mutant of Escherichia coli enterotoxin inducing a specific Thl-type of T cells to varicella-zoster vaccine enhances the production of IL-12 by IFNgamma-stimulated macrophages. Vaccine 24 (2006) 3719-3726
30. Tsuji T., Yokochi T., Kamiya H., Kawamoto Y., Miyama A., and Asano Y. Relationship between low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology 90 (1997) 176-182
31. Sasaki K., Kato M., Takahashi T., Ochi S., Ichinose Y., Shiraki K., et al. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice. J Med Virol 70 (2003) 329-335
32. Neri P., Nagano S.I., Yokoyama S., Dohi H., Kobayashi K., Miura T., et al. Neutralizing Activity of Polyvalent Gb(3), Gb(2) and Galacto-Trehalose Models against Shiga Toxins. Microbiol Immunol 51 (2007) 581-592
33. Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M., et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem 280 (2005) 35164-35171
34. Boyd B., Richardson S., and Gariepy J. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin. Infect Immun 59 (1991) 750-757
35. Acheson D.W., Levine M.M., Kaper J.B., and Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 64 (1996) 355-357
36. Butterton J.R., Ryan E.T., Acheson D.W., and Calderwood S.B. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun 65 (1997) 2127-2135
37. Byun Y., Ohmura M., Fujihashi K., Yamamoto S., McGhee J.R., Udaka S., et al. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 19 (2001) 2061-2070